Nonalcoholic fatty liver disease, an accumulation of fat in the liver, is estimated to occur in almost 1 in 5 adults. With 2 of the most common risk factors being obesity and diabetes, its prevalence is growing. Nonalcoholic steatohepatitis is a more severe form of nonalcoholic fatty liver disease. There are currently no approved drugs to treat nonalcoholic steatohepatitis, but several drugs are being developed to treat this disease.
CarrRMOranuAKhungarV. Nonalcoholic fatty liver disease: pathophysiology and management. Gastroenterol Clin North Am. 2016;45(4):639–652.
2.
LazoMHernaezREberhardtMSet al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 2013;178(1):38–45.
3.
YounossiZMOtgonsurenMHenryLet al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatol. 2015;62:1723–1730.
4.
SinghSAllenAMWangZProkopLJMuradMHLoombaR. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–654.
5.
MussoGCassaderMRosinaFGambinoR. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55:885–904.
6.
ChalasaniNYounossiZLavineJEet al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357. doi:10.1002/hep.29367.
7.
SafadiRKonikoffFMMahamidMet al. The fatty acid-bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12(12):2085–2091.
8.
LoombaRLawitzEMantryPSet al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology. 2018;67(2):549–559.
